Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis

Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Shuko Murakami, Takako Inoue, Keita Kuroyanagi, Hayato Kawamura, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka

Open source

DOI: 10.1111/jgh.16672
Published: 2024-06-28
Container: Journal of Gastroenterology and Hepatology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jgh.16672,
  title = {Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis},
  author = {Takanori Suzuki and Kentaro Matsuura and Yuta Suzuki and Fumihiro Okumura and Yoshihito Nagura and Satoshi Sobue and Sho Matoya and Tomokatsu Miyaki and Yoshihide Kimura and Atsunori Kusakabe and Satoshi Narahara and Takayuki Tokunaga and Katsuya Nagaoka and Shuko Murakami and Takako Inoue and Keita Kuroyanagi and Hayato Kawamura and Kei Fujiwara and Shunsuke Nojiri and Hiromi Kataoka and Yasuhito Tanaka},
  year = {2024},
  journal = {Journal of Gastroenterology and Hepatology},
  doi = {10.1111/jgh.16672},
  url = {https://doi.org/10.1111/jgh.16672}
}

RIS

TY  - JOUR
TI  - Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis
AU  - Takanori Suzuki
AU  - Kentaro Matsuura
AU  - Yuta Suzuki
AU  - Fumihiro Okumura
AU  - Yoshihito Nagura
AU  - Satoshi Sobue
AU  - Sho Matoya
AU  - Tomokatsu Miyaki
AU  - Yoshihide Kimura
AU  - Atsunori Kusakabe
AU  - Satoshi Narahara
AU  - Takayuki Tokunaga
AU  - Katsuya Nagaoka
AU  - Shuko Murakami
AU  - Takako Inoue
AU  - Keita Kuroyanagi
AU  - Hayato Kawamura
AU  - Kei Fujiwara
AU  - Shunsuke Nojiri
AU  - Hiromi Kataoka
AU  - Yasuhito Tanaka
PY  - 2024
JO  - Journal of Gastroenterology and Hepatology
DO  - 10.1111/jgh.16672
UR  - https://doi.org/10.1111/jgh.16672
ER  -

APA

Suzuki, T., Matsuura, K., Suzuki, Y., Okumura, F., Nagura, Y., Sobue, S., Matoya, S., Miyaki, T., Kimura, Y., Kusakabe, A., Narahara, S., Tokunaga, T., Nagaoka, K., Murakami, S., Inoue, T., Kuroyanagi, K., Kawamura, H., Fujiwara, K., Nojiri, S., Kataoka, H., & Tanaka, Y. (2024). Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16672

Source records

crossref · retrieved 2026-09-27T00:30:38.467Z